The emergence of CBD in Europe could be informed by lessons taken from the North American marketplace. 

Driven by the increasing amount of jurisdictions that have legalized the sale of cannabis, the explosion of the CBD market across North America has spawned a number of subsectors within the industry including nutritional foods, topical products, sports supplements, and more. Driven by the increased amount of legal research and development regarding cannabidiol and its potential remedial effects, the CBD market in the United States grew to reach US$1.9 billion according to BDS Analytics.

With lower regulatory hurdles to clear than psychoactive cannabis, CBD product sales have grown at a faster rate than overall dispensary sales, indicating the potential for cannabidiol as its own major industry. “We’re witnessing CBD maturing from a cannabis sub-category into a full-blown industry of its own,” said Roy Bingham, Co-Founder and CEO of BDS Analytics. While the growth of the CBD market and its many applications have come with regulatory complications, early breakthroughs in North America have the potential to inform emerging cannabidiol markets around the world. Following a similar trajectory, CBD in Europe has already grown to become its own major industry.

world high life logo

This INNspired Article is brought to you by:

World High Life Plc (AQSE:LIFE, OTCQB:WRHLF) is a cannabis investment company specializing in the emerging CBD market, specifically the growing market in the United Kingdom and emerging European markets.Send me an Investor Kit

Regulating CBD in Europe

Home to more than 740 million people, Europe has twice the population size of Canada and the US combined. The legal status of psychoactive cannabis varies across Europe, but cannabidiol has proven to be more easily accepted across the continent. Products containing CBD are currently considered a “novel food” under European Union regulations. Novel foods in the European Union are recognized as foods that had not been used for human consumption to a significant extent before May 15th, 1997. While CBD’s novel food status could pose challenges to the European CBD market, analysts at Brightfield Group estimated the industry reached $318 million in 2018.

“CBD is just starting to take hold in Europe, with both product availability and consumer awareness still quite limited. This is a great opportunity for developed brands to enter and expand through Europe with far less competition than we’re seeing in the US,” said Brightfield Managing Director Bethany Gomez. “With the Novel Foods Act, it is a challenging legal environment to operate in, but impending regulatory changes are likely to smooth the way for significant mid-term growth.”

Medical cannabis and CBD in Europe

As shown by the early proliferation of the North American CBD market, the remedial benefits of cannabidiol can be applied to a variety of existing products including cosmetics, nutritional foods and beverages. While these products have shown significant potential, the unique wide-ranging applications of cannabidiol can pose a variety of challenges to regulators and businesses.

From the perspective of cannabis companies, the various designations can have a significant impact on how CBD in Europe is defined and regulated. “The CBD industry, like any consumer market, is subject to a range of generic regulations governing food, cosmetics and medicines, and the end product category determines the rules by which those products can be produced, distributed and marketed,” said a 2019 report on CBD in the UK written by the Centre for Medicinal Cannabis.

While the unregulated nature of the UK CBD market could pose early challenges for the industry, the market has already reached a total of $374 million in 2019 according to Nate Erskine, the head market analyst at CBD-Intel. In pursuit of the emerging opportunity in the United Kingdom, a number of cannabis companies have begun to make inroads in the country’s medical cannabis and cannabidiol industries. In 2019 cannabis titans Canopy Growth Corp’s (TSX:WEED,NYSE:CGC) pharmaceutical business, Spectrum Therapeutics, received the first UK license for a storage and distribution facility dedicated to medical cannabis. The company is working to serve new medical cannabis patients in the UK.

Targeting the UK CBD industry, medical cannabis investment company World High Life (OTCQB:WRHLF,AQSE:LIFE) acquired Love Hemp, a leading provider of CBD-based products in the United Kingdom, in 2019. “Our mandate was to find the innovators positioned where the Canopy’s of the world were 5-7 years ago. Most importantly, we were looking for leaders who were passionate about the industry and their business, people who had a vision and were seeking both capital and expertise to realize that vision. With Tony Calamita and Tom Rowlands, founders of Love Hemp, we met all of our criteria for success,” said World High Life CEO David Stadnyk.

Love Hemp offers CBD-based oils, edibles, cosmetics and vaporizer products that are distributed in over 2000 retail locations across the United Kingdom, including stores such as Ocado, Holland & Barrett, WH Smith and the company’s online retailer, CBDOilsUK. Love Hemp recently announced it had increased its online sales by 39 percent month-over-month since January of 2020 and is now in the process of negotiation with some of the UK’s largest retailers for potential product listings in September 2020.

Takeaway

Following in the footsteps of the North American market, many European authorities have prioritized cannabidiol and medical cannabis over the recreational use of THC. While regulatory questions left to be answered could pose challenges for both businesses and governments, companies capable of establishing a foothold in these nascent markets could benefit from a first-mover advantage in the European cannabis space.

This article was originally published by the Investing News Network in June 2020.


This INNSpired article is sponsored by World High Life (OTCQB:WRHLF,AQSE:LIFE). This INNSpired article provides information that was sourced by the Investing News Network (INN) and approved by World High Life in order to help investors learn more about the company. World High Life is a client of INN. The company’s campaign fees pay for INN to create and update this INNSpired article.

This INNSpired article was written according to INN editorial standards to educate investors.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services, or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with World High Life and seek advice from a qualified investment advisor.

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less